{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T08:44:46Z","timestamp":1794386686864,"version":"4.9.0"},"publisher-location":"Totowa, NJ","reference-count":30,"publisher":"Humana Press","isbn-type":[{"value":"9781617790799","type":"print"},{"value":"9781617790805","type":"electronic"}],"license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011]]},"DOI":"10.1007\/978-1-61779-080-5_33","type":"book-chapter","created":{"date-parts":[[2011,4,20]],"date-time":"2011-04-20T12:35:46Z","timestamp":1303302946000},"page":"407-419","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Development of Rituximab-Resistant B-NHL Clones: An In Vitro Model for Studying Tumor Resistance to Monoclonal Antibody-Mediated Immunotherapy"],"prefix":"10.1007","author":[{"given":"Ali R.","family":"Jazirehi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Bonavida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,3,24]]},"reference":[{"key":"33_CR1_33","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1097\/00001813-200211002-00007","volume":"2","author":"B Coiffier","year":"2002","unstructured":"Coiffier, B., Pfreundschuh, M., Stahel, R., Vose, J., and Zinzani, P.L. (2002) Aggressive lymphoma: improving treatment outcome with rituximab. Anticancer Drugs\n                2, S43\u201350.","journal-title":"Anticancer Drugs"},{"key":"33_CR2_33","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1182\/blood.V63.6.1424.1424","volume":"63","author":"KC Andeson","year":"1984","unstructured":"Andeson, K.C., Bates, M.P., Slaughenhoupt, B.L., Pinkus, G.S., Schlossman, S.F., and Nadler L.M. (1984) Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood\n                63, 1424\u201333.","journal-title":"Blood"},{"key":"33_CR3_33","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1182\/blood.V69.2.584.584","volume":"69","author":"OW Press","year":"1987","unstructured":"Press, O.W., Appelbaum, F., Ledbetter, J.A., et al. (1987) Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood\n                69, 584\u201391.","journal-title":"Blood"},{"key":"33_CR4_33","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/j.1460-2075.1988.tb02867.x","volume":"7","author":"DA Einfeld","year":"1988","unstructured":"Einfeld, D.A., Brown, J.P., Valentine, M.A., Clark, E.A., and Ledbetter, J.A. (1988) Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J\n                7, 711\u20137.","journal-title":"EMBO J"},{"key":"33_CR5_33","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/BF02982803","volume":"76","author":"AJ Grillo-Lopez","year":"2002","unstructured":"Grillo-Lopez, A.J. (2002) Monoclonal antibody therapy for B-cell lymphoma. Int J Hematol\n                76, 385\u201393.","journal-title":"Int J Hematol"},{"key":"33_CR6_33","first-page":"709","volume":"3","author":"S Alas","year":"2001","unstructured":"Alas, S., Emmanouilides, C., and Bonavida, B. (2001) Inhibition of interleukin 10 by rituximab results in down-regulation of Bcl-2 and sensitization of B-cell non-Hodgkin\u2019s lymphoma to apoptosis. Clin Cancer Res\n                3, 709\u2013723.","journal-title":"Clin Cancer Res"},{"key":"33_CR7_33","first-page":"316","volume":"1","author":"S Alas","year":"2003","unstructured":"Alas, S., and Bonavida B. (2003) Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin\u2019s lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. Clin Cancer Res\n                1, 316\u2013326.","journal-title":"Clin Cancer Res"},{"key":"33_CR8_33","first-page":"1183","volume":"2","author":"AR Jazirehi","year":"2003","unstructured":"Jazirehi, A.R., Gan, X-H., De Vos, S., Emmanouilides, C., and Bonavida, B. (2003) Rituximab (anti-CD20) selectively modifies Bcl-xL and Apaf-1 expression and sensitizes human non-Hodgkin\u2019s lymphoma B cell lines to paclitaxel-induced apoptosis. Mol Cancer Ther\n                2, 1183\u201393.","journal-title":"Mol Cancer Ther"},{"key":"33_CR9_33","doi-asserted-by":"publisher","first-page":"7117","DOI":"10.1158\/0008-5472.CAN-03-3500","volume":"64","author":"AR Jazirehi","year":"2004","unstructured":"Jazirehi, A.R., Vega, M., Chatterjee, D., Goodglick, L., and Bonavida, B. (2004) Inhibition of the Raf-MEK1\/2-ERK1\/2 signaling pathway, Bcl-xL down-regulation, and chemo-sensitization of non-Hodgkin\u2019s lymphoma B-cells by Rituximab. Cancer Res\n                64, 7117\u201326.","journal-title":"Cancer Res"},{"key":"33_CR10_33","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/0008-5472.264.65.1","volume":"65","author":"AR Jazirehi","year":"2005","unstructured":"Jazirehi, A.R., Huerta, S., Cheng, G., and Bonavida, B. (2005) Rituximab (chimeric anti -CD20 mAb) inhibits the constitutive NF-\u03baB signaling pathway in non-Hodgkin\u2019s lymphoma (NHL) B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis. Cancer Res\n                65, 264\u201376.","journal-title":"Cancer Res"},{"key":"33_CR11_33","doi-asserted-by":"publisher","first-page":"3530","DOI":"10.1038\/sj.onc.1207336","volume":"23","author":"MI Vega","year":"2004","unstructured":"Vega, M.I., Huerta-Yepaz, S., Garban, H., Jazirehi, A.R., Emmanouilides, C., and Bonavida B. (2004) Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance. Oncogene\n                23, 3530\u20133540.","journal-title":"Oncogene"},{"key":"33_CR12_33","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1080\/10428190802357071","volume":"10","author":"MI Vega","year":"2008","unstructured":"Vega, M.I., Martinez-Paniagua, M., Jazirehi, A.R., Huerta-Yepez, S., Umezawa, K., Martinez-Maza, O., and Bonavida, B. (2008) The NF-kappaB inhibitors (bortezomib and DHMEQ) sensitise rituximab-resistant AIDS-B-non-Hodgkin lymphoma to apoptosis by various chemotherapeutic drugs. Leuk Lymphoma\n                10, 1982\u201394.","journal-title":"Leuk Lymphoma"},{"key":"33_CR13_33","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1053\/sonc.2002.30152","volume":"1","author":"MS Czuczman","year":"2002","unstructured":"Czuczman, M.S., Fallon, A., Mohr, A., Stewart, C., Bernstein, Z.P., McCarthy, P., et al. (2002) Rituximab in combination with CHOP or fludarabine in low-grade lymphoma. Semin Oncol\n                1, 36\u201340.","journal-title":"Semin Oncol"},{"key":"33_CR14_33","first-page":"1927","volume":"92","author":"B Coiffier","year":"1998","unstructured":"Coiffier, B., Haioun, C., Ketterer, N., Engert, A., Tilly, H., Ma D, et al. (1998) Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood\n                92, 1927\u20131932.","journal-title":"Blood"},{"key":"33_CR15_33","doi-asserted-by":"publisher","first-page":"6421","DOI":"10.1200\/JCO.2005.06.004","volume":"23","author":"DG Maloney","year":"2005","unstructured":"Maloney, D.G. (2005) Immunotherapy for non-Hodgkin\u2019s lymphoma: monoclonal antibodies and vaccines. J Clin Oncol\n                23, 6421\u20138.","journal-title":"J Clin Oncol"},{"key":"33_CR16_33","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1038\/sj.onc.1208349","volume":"24","author":"AR Jazirehi","year":"2005","unstructured":"Jazirehi, A.R., and Bonavida, B. (2005) Molecular and cellular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin\u2019s lymphoma: mplications in chemo-sensitization and therapeutic. Oncogene\n                24, 2121\u201343.","journal-title":"Oncogene"},{"key":"33_CR17_33","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/35055095","volume":"3","author":"S-P Tzung","year":"2001","unstructured":"Tzung, S-P., Kim, C.M., Basanez, G., et al. (2001) Antimycin A mimics a cell death-inducing Bcl-2 homology domain 3. Nat Cell Biol\n                3, 183\u201391.","journal-title":"Nat Cell Biol"},{"key":"33_CR18_33","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","volume":"83","author":"ME Reff","year":"1994","unstructured":"Reff, M.E., Carner, K., Chambers, K.S., et al. (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood\n                83, 435\u20135.","journal-title":"Blood"},{"key":"33_CR19_33","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","volume":"16","author":"P McLaughlin","year":"1998","unstructured":"McLaughlin, P., Grillo-Lopez, A.J., Link, B.K., Levy, R., Czuczman, M.S., Williams, M.E., et al. (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol\n                16, 2825\u20132833.","journal-title":"J Clin Oncol"},{"key":"33_CR20_33","doi-asserted-by":"crossref","unstructured":"Pickartz, T., Ringel, F., Wedde, M., Renz, H., Klein, A., von, N.N., et al. (2001) Selection of B-cell chronic lymphocytic leukemia cell variants by therapy with anti-CD20 monoclonal antibody rituximab. Exp Hematol\n                12: 1410\u20131416.","DOI":"10.1016\/S0301-472X(01)00753-6"},{"key":"33_CR21_33","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1182\/blood-2004-01-0277","volume":"104","author":"C Bezombes","year":"2004","unstructured":"Bezombes, C., Grazide, S., Garret, C., et al. (2004) Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains. Blood\n                104, 1166\u201373.","journal-title":"Blood"},{"key":"33_CR22_33","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1097\/00002371-200105000-00011","volume":"24","author":"SP Treon","year":"2001","unstructured":"Treon, S.P., Mitsiades, C., Mitsiades, N., Young, G., Doss, D., Schlossman, R., et al. (2001) Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-Cell malignancies. J Immunother\n                24, 263\u2013271.","journal-title":"J Immunother"},{"key":"33_CR23_33","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1182\/blood.V98.5.1352","volume":"98","author":"WK Weng","year":"2001","unstructured":"Weng, W.K., and Levy, R. (2001) Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. Blood\n                98, 1352\u20131357.","journal-title":"Blood"},{"key":"33_CR24_33","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1158\/0008-5472.CAN-06-2184","volume":"67","author":"AR Jazirehi","year":"2007","unstructured":"Jazirehi, A.R., Vega, M.I., and Bonavida, B. (2007) Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy. Cancer Res\n                67, 1270\u201381.","journal-title":"Cancer Res"},{"key":"33_CR25_33","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1182\/blood-2002-06-1639","volume":"101","author":"T Manshouri","year":"2003","unstructured":"Manshouri, T., Do, K.A., Wang, X., et al. (2003) Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood\n                101, 2507\u201313.","journal-title":"Blood"},{"key":"33_CR26_33","doi-asserted-by":"publisher","first-page":"2934","DOI":"10.1038\/sj.onc.1207515","volume":"23","author":"Y Pommier","year":"2004","unstructured":"Pommier, Y., Sordet, O., Antony, S., Hayward, R.L., and Kohn, K.W. (2004) Apoptosis defects and chemo-therapy resistance: molecular interaction maps and networks. Oncogene\n                23, 2934\u20134.","journal-title":"Oncogene"},{"key":"33_CR27_33","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1200\/JCO.2005.02.050","volume":"23","author":"OA O\u2019Connor","year":"2005","unstructured":"O\u2019Connor, O.A., Wright, J., Moskowitz, C., et al. (2005) Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin\u2019s lymphoma and mantle cell lymphoma. J Clin Oncol\n                23, 676\u201384.","journal-title":"J Clin Oncol"},{"key":"33_CR28_33","first-page":"24626","volume":"277","author":"A Ariga","year":"2002","unstructured":"Ariga, A., Namekawa, J., Matsumoto, N., Inoue, J., and Umezawa, K. (2002) Inhibition of tumor necrosis factor--induced nuclear translocation and activation of NF-B by dehydroxymethylepoxyquino- micin. J Biol Chem\n                277, 24626\u201330.","journal-title":"J Biol Chem"},{"key":"33_CR29_33","first-page":"107","volume":"63","author":"E Kikuchi","year":"2003","unstructured":"Kikuchi, E., Horiguhi, Y., Nakashima, J., et al. (2003) Suppression of hormone-refractory prostate cancer by a novel nuclear factor B inhibitor in nude mice. Cancer Res\n                63, 107\u201310.","journal-title":"Cancer Res"},{"key":"33_CR30_33","doi-asserted-by":"publisher","first-page":"27489","DOI":"10.1074\/jbc.270.46.27489","volume":"270","author":"DR Alessi","year":"1995","unstructured":"Alessi, D.R., Cuenda, A., Cohen, P., Dudley, D.T., and Saltiel, A.R. (1995) PD098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem\n                270, 27489\u201394.","journal-title":"J Biol Chem"}],"container-title":["Methods in Molecular Biology","Cancer Cell Culture"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-61779-080-5_33","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T19:45:25Z","timestamp":1675712725000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-61779-080-5_33"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011]]},"ISBN":["9781617790799","9781617790805"],"references-count":30,"URL":"https:\/\/doi.org\/10.1007\/978-1-61779-080-5_33","relation":{"is-part-of":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1007\/978-1-61779-080-5","asserted-by":"object"}]},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011]]},"assertion":[{"value":"24 March 2011","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}